Alkem Laboratories

Market Cap (₹ Cr.)

₹74,370

52 Week High

6,439.90

Book Value

₹862

52 Week Low

3,447.00

PE Ratio

34.59

PB Ratio

7.21

PE for Sector

39.11

PB for Sector

4.60

ROE

16.91 %

ROCE

41.36 %

Dividend Yield

0.64 %

EPS

₹179.80

Industry

Pharmaceuticals

Sector

Pharmaceuticals - Indian - Bulk Drugs & Formln

Investment Returns

In Long Term

In Short Term

1 Year

0.00%

2 Years

0.00%

3 Years

0.00%

4 Years

0.00%

5 Years

0.00%

Growth Rate

Revenue Growth

9.84 %

Net Income Growth

79.92 %

Cash Flow Change

15.78 %

ROE

58.44 %

ROCE

47.24 %

EBITDA Margin (Avg.)

27.48 %

Financial Results

Quarterly Financials	Mar 2015	Jun 2015	Sept 2015	Dec 2015	Mar 2016	Jun 2016	Sept 2016	Dec 2016	Mar 2017	Jun 2017	Sept 2017	Dec 2017	Mar 2018	Jun 2018	Sept 2018	Dec 2018	Mar 2019	Jun 2019	Sept 2019	Dec 2019	Mar 2020	Jun 2020	Sept 2020	Dec 2020	Mar 2021	Jun 2021	Sept 2021	Dec 2021	Mar 2022	Jun 2022	Sept 2022	Dec 2022	Mar 2023	Jun 2023	Sept 2023	Dec 2023	Mar 2024	Jun 2024
Revenue	811	990	1,178	1,046	973	1,208	1,358	1,184	1,036	1,168	1,588	1,445	1,180	1,289	1,464	1,541	1,487	1,511	1,925	1,623	1,713	1,583	2,009	1,851	1,966	2,318	2,407	2,244	2,061	2,114	2,535	2,357	2,315	2,318	2,696	2,590	2,449	2,606
Expenses	654	784	882	781	767	927	1,027	940	896	993	1,126	1,109	1,080	1,090	1,137	1,212	1,230	1,233	1,410	1,233	1,334	1,044	1,390	1,336	1,514	1,728	1,776	1,709	1,807	1,875	2,056	1,841	1,906	1,919	1,980	1,977	1,970	1,879
EBITDA	157	206	295	264	206	280	331	244	139	175	463	336	100	200	327	329	257	278	516	390	380	539	619	516	452	590	631	536	254	239	479	517	409	398	716	614	479	727
Operating Profit %	12 %	16 %	20 %	22 %	10 %	21 %	23 %	19 %	11 %	13 %	28 %	22 %	7 %	14 %	21 %	21 %	16 %	18 %	26 %	23 %	21 %	32 %	30 %	25 %	21 %	24 %	25 %	22 %	10 %	9 %	16 %	20 %	15 %	15 %	25 %	21 %	17 %	25 %
Depreciation	17	17	21	18	18	18	19	20	20	23	26	28	30	32	33	35	41	40	40	43	64	48	52	50	49	52	54	58	55	57	58	58	57	58	59	58	69	64
Interest	17	20	17	15	8	5	7	7	5	8	11	7	6	10	9	7	1	9	10	10	10	12	15	9	7	9	9	7	13	22	20	23	22	21	19	21	21	21
Profit Before Tax	123	169	258	232	180	257	305	217	115	144	426	301	64	158	285	287	215	229	465	338	306	479	553	457	396	529	569	470	186	160	402	436	330	319	639	534	389	641
Tax	-27	-3	10	19	17	54	62	-98	28	30	91	82	-1	34	62	59	46	53	72	24	98	83	97	80	71	92	99	81	32	28	70	76	54	54	111	90	77	111
Net Profit	122	172	248	213	67	251	295	214	123	112	331	213	60	129	238	241	191	211	434	349	271	426	495	401	363	469	558	437	77	140	351	389	255	271	647	504	325	583
EPS in ₹	10.24	14.36	20.78	17.81	5.62	21.03	24.68	17.87	10.27	9.38	27.66	17.81	5.02	10.83	19.93	20.18	15.96	17.62	36.30	29.15	22.68	35.64	41.42	33.54	30.34	39.25	46.67	36.56	6.43	11.72	29.33	32.53	21.31	22.70	54.07	42.17	27.18	48.78

Show % Change

Above figures are in Rs. Crores

Balance Sheet

Balance Sheet	2015	2016	2017	2018	2019	2020	2021	2022	2023	2024
Total Assets	4,861	4,822	5,898	6,814	7,292	9,106	10,773	13,169	12,731	14,038
Fixed Assets	870	875	1,126	1,471	1,606	1,837	1,758	1,882	1,825	1,782
Current Assets	1,777	2,079	2,268	3,032	3,081	4,229	5,632	6,861	6,772	8,040
Capital Work in Progress	96	147	218	299	382	314	323	232	229	91
Investments	60	1,158	1,518	1,545	1,696	1,956	2,152	2,529	3,006	2,829
Other Assets	3,835	2,644	3,037	3,500	3,609	4,999	6,539	8,526	7,672	9,336
Total Liabilities	1,760	1,223	1,506	1,929	1,827	2,825	3,147	4,426	3,381	3,483
Current Liabilities	1,603	1,154	1,413	1,787	1,670	2,580	2,910	4,124	3,045	3,106
Non Current Liabilities	157	69	92	142	157	246	237	302	337	377
Total Equity	3,101	3,600	4,393	4,885	5,465	6,280	7,626	8,744	9,350	10,555
Reserve & Surplus	3,077	3,576	4,369	4,861	5,441	6,257	7,602	8,720	9,326	10,531
Share Capital	24	24	24	24	24	24	24	24	24	24

Show % Change

Above figures are in Rs. Crores

Cash Flow

Cash Flow	2015	2016	2017	2018	2019	2020	2021	2022	2023	2024
Net Cash Flow	8	-17	13	-15	156	-141	-5	67	-77	-138
Investing Activities	-260	311	-362	-273	-313	-995	-1,121	-1,669	197	-866
Operating Activities	242	630	499	318	745	682	1,324	1,299	1,437	1,687
Financing Activities	26	-958	-125	-60	-276	173	-209	437	-1,711	-959

Show % Change

Above figures are in Rs. Crores

Share Holding

% Holding	Mar 2021	Jun 2021	Sept 2021	Dec 2021	Mar 2022	Jun 2022	Sept 2022	Dec 2022	Mar 2023	Jun 2023	Sept 2023	Dec 2023	Mar 2024	Jun 2024
Promoter	60.16 %	58.84 %	58.84 %	57.13 %	57.13 %	57.14 %	57.16 %	57.16 %	57.16 %	57.16 %	56.74 %	56.74 %	56.74 %	56.38 %
FIIs	4.42 %	4.50 %	5.33 %	5.40 %	5.41 %	5.67 %	4.46 %	4.41 %	4.44 %	5.64 %	6.03 %	8.49 %	9.11 %	8.69 %
DIIs	13.20 %	14.49 %	13.99 %	13.94 %	14.14 %	14.10 %	15.74 %	16.44 %	16.69 %	16.34 %	17.64 %	15.91 %	15.63 %	18.57 %
Government	0.00 %	0.00 %	0.00 %	0.00 %	0.00 %	0.00 %	0.00 %	0.00 %	0.00 %	0.00 %	0.00 %	0.00 %	0.00 %	0.00 %
Public / Retail	22.22 %	22.17 %	21.84 %	23.53 %	23.32 %	23.09 %	22.65 %	21.99 %	21.70 %	20.86 %	19.59 %	18.86 %	18.52 %	16.36 %

Show % Change

Peer Comparison Compare Peers on Screener

Competitors	LTP	Market Cap (₹ Cr.)	P/E Ratio	Revenue (₹ Cr.)	YoY Revenue Growth %	Net Profit (₹ Cr.)	YoY Profit Growth %	RSI
Sun Pharmaceutical	1,836.00	4,47,691.91	42.46	49,887.17	12.06	9,648	42.62	61.03
Cipla	1,651.60	1,34,956.56	30.36	26,520.66	14.17	4,155	17.77	60.15
Zydus Life Science	1,079.95	1,11,727.19	26.80	19,831.50	13.82	3,831	30.78	34.07
Dr Reddys Laboratories	6,567.80	1,10,648.92	19.88	28,905.40	12.36	5,578	-0.90	36.38
Lupin	2,224.95	1,03,570.56	45.76	20,141.50	19.94	1,936	77.69	59.35
Mankind Pharma	2,395.60	98,296.04	50.09	10,615.63	19.57	1,942	9.89	53.00
Aurobindo Pharma	1,539.15	90,940.60	25.35	29,559.25	17.55	3,169	61.17	55.58
Alkem Laboratories	6,090.30	74,370.03	34.59	12,978.42	9.84	1,811	91.18	53.74
Glenmark Pharmaceuticals	1,646.05	48,348.71	-	12,653.09	6.58	-1,831	96.52	48.26
Biocon	363.65	45,082.53	28.88	15,621.20	35.25	1,298	478.78	48.38